Showing results (1201-1210 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|July 25, 2025
CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected CasesNishi Shah, Melissa Suchanek, Astha Thakkar, et al.
JCO Precision Oncology|March 28, 2025
Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS CohortWeisong Zhao, Huanliang Meng, Zhenwu Dai, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
JCO Precision Oncology|November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate CancerAndrew J Armstrong, Jun Luo, David M Nanus, et al.
JCO Precision Oncology|November 9, 2020
Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children's Oncology GroupBrandon J Diessner, Nathan Pankratz, Anthony J Hooten, et al.
JCO Precision Oncology|September 9, 2020
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of HeterozygosityEthan S Sokol, Dean Pavlick, Hossein Khiabanian, et al.
JCO Precision Oncology|January 9, 2023
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural VariationsEmily L Hoskins, Eric Samorodnitsky, Michele R Wing, et al.
JCO Precision Oncology|January 5, 2023
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
JCO Precision Oncology|June 21, 2021
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your StatisticianShing M Lee, Nolan A Wages, Karyn A Goodman, et al.
JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.
Pageof 140